Full-Time

Senior Director

Clinical Development

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$340k - $375k/yr

+ Bonus + Equity

San Francisco, CA, USA

Hybrid

Hybrid schedule with some on-site days in San Francisco, CA.

Category
Biology & Biotech (1)

Get referred to BridgeBio

Find people who can refer or advise you

Requirements
  • MD or equivalent medical degree required; board certification in Endocrinology, Nephrology, or a related specialty preferred.
  • 5+ years of biotechnology, pharmaceutical, or clinical development experience with increasing medical leadership responsibilities.
  • Experience in rare disease, endocrinology, metabolic disease, or chronic hypoparathyroidism drug development strongly preferred.
  • Demonstrated expertise in clinical trial design, medical monitoring, protocol development, data interpretation, and regulatory interactions.
  • Strong understanding of ICH-GCP, FDA, EMA, and global regulatory requirements.
  • Exceptional communication, collaboration, and stakeholder management skills with the ability to influence across functions.
  • Patient-focused, intellectually curious, and motivated to thrive in a fast-paced, mission-driven biotechnology environment.
Responsibilities
  • Serve as the medical lead for one or more clinical programs, providing strategic and operational leadership across study design, execution, analysis, and reporting.
  • Lead cross-functional clinical study teams and provide medical oversight to ensure participant safety, data quality, protocol compliance, and study interpretability.
  • Partner with investigators, key opinion leaders, advocacy organizations, and CRO partners to execute high-quality clinical trials.
  • Author and review protocols, investigator brochures, clinical study reports, DSURs, informed consent documents, and regulatory submission content.
  • Lead medical monitoring activities and contribute to safety review meetings, investigator meetings, and regulatory authority interactions.
  • Translate clinical, translational, and nonclinical findings into actionable development strategies and lifecycle plans.
  • Represent Calcilytix at scientific congresses and maintain awareness of emerging developments in chronic hypoparathyroidism, endocrinology, and rare disease drug development.
Desired Qualifications
  • Board certification in Endocrinology, Nephrology, or a related specialty preferred;
  • Experience in rare disease, endocrinology, metabolic disease, or chronic hypoparathyroidism drug development strongly preferred.

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Get referred to BridgeBio

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby generated $362.4 million US sales in 2025 following AstraZeneca's Wainua trial failure.
  • Three Phase III readouts for encaleret, infigratinib, and BBP-418 expected in fall 2025 to early 2026.
  • Global ATTR therapy market opportunity exceeds $20 billion with DKSH partnership expanding Asia Pacific access.

What critics are saying

  • Rinascera Therapeutics launched July 2026 with RIN-002, directly eroding BridgeBio's potential dermatology franchise revenue.
  • Operating margin of -87% and 93% revenue reliance on Attruby creates existential vulnerability before pipeline inflection.
  • $750 million credit facility increases leverage risk if Phase 3 readouts for encaleret or BBP-418 delay beyond 2026.

What makes BridgeBio unique

  • Decentralized hub-and-spoke model creates autonomous subsidiaries for specific genetic diseases.
  • Focuses exclusively on Mendelian diseases with well-understood single-gene genetic drivers.
  • Rapid capital reallocation and data-driven decision-making across 15+ drug programs simultaneously.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

3%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.